(BRC) Brady - Overview
Stock: Safety Signs, Labeling Systems, RFID Tags, Patient Wristbands, Access Badges
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.34% |
| Yield on Cost 5y | 2.08% |
| Yield CAGR 5y | 2.19% |
| Payout Consistency | 96.6% |
| Payout Ratio | 20.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.7% |
| Relative Tail Risk | -9.79% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.85 |
| Alpha | 13.12 |
| Character TTM | |
|---|---|
| Beta | 0.644 |
| Beta Downside | 0.617 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.98% |
| CAGR/Max DD | 1.40 |
Description: BRC Brady January 11, 2026
Brady Corporation (NYSE:BRC) designs, manufactures, and distributes a broad portfolio of identification and workplace-safety solutions-including safety signs, lockout/tagout devices, RFID/barcode scanners, and handheld printers-serving industrial, healthcare, aerospace, and government customers across the Americas, Europe, Asia, and Australia.
The company reaches end-users through a hybrid go-to-market model that blends independent distributors, a direct sales force, and expanding digital channels, allowing it to capture both high-volume commodity sales and higher-margin custom solutions.
Key financial snapshots (FY 2023): revenue ≈ $1.73 billion, operating margin ≈ 12.5 %, free-cash-flow conversion ≈ 85 %, and a dividend yield of roughly 2.4 %. The balance sheet is solid, with a debt-to-equity ratio of 0.45 and a return on invested capital (ROIC) near 13 %.
Primary growth catalysts include tightening occupational-health-and-safety regulations (e.g., OSHA and EU directives), accelerating adoption of RFID and barcode technologies in supply-chain digitization, and rising capital-expenditure cycles in infrastructure, renewable-energy, and automotive sectors-all of which boost demand for labeling, asset-tracking, and compliance-software services.
Investors seeking a deeper, data-driven assessment of Brady’s valuation and risk profile may find the analytics on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 196.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.29 > 1.0 |
| NWC/Revenue: 22.16% < 20% (prev 18.36%; Δ 3.80% < -1%) |
| CFO/TA 0.11 > 3% & CFO 191.1m > Net Income 196.4m |
| Net Debt (-5.90m) to EBITDA (292.9m): -0.02 < 3 |
| Current Ratio: 2.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.7m) vs 12m ago -1.01% < -2% |
| Gross Margin: 50.59% > 18% (prev 0.51%; Δ 5008 % > 0.5%) |
| Asset Turnover: 90.10% > 50% (prev 85.17%; Δ 4.93% > 0%) |
| Interest Coverage Ratio: 54.66 > 6 (EBITDA TTM 292.9m / Interest Expense TTM 4.60m) |
Altman Z'' 7.14
| A: 0.19 (Total Current Assets 662.4m - Total Current Liabilities 320.7m) / Total Assets 1.79b |
| B: 0.76 (Retained Earnings 1.36b / Total Assets 1.79b) |
| C: 0.15 (EBIT TTM 251.4m / Avg Total Assets 1.71b) |
| D: 2.32 (Book Value of Equity 1.27b / Total Liabilities 549.9m) |
| Altman-Z'' Score: 7.14 = AAA |
Beneish M -2.97
| DSRI: 1.02 (Receivables 248.6m/218.3m, Revenue 1.54b/1.39b) |
| GMI: 1.01 (GM 50.59% / 50.90%) |
| AQI: 0.92 (AQ_t 0.47 / AQ_t-1 0.51) |
| SGI: 1.11 (Revenue 1.54b / 1.39b) |
| TATA: 0.00 (NI 196.4m - CFO 191.1m) / TA 1.79b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of BRC shares?
Over the past week, the price has changed by +6.72%, over one month by +14.65%, over three months by +23.84% and over the past year by +24.47%.
Is BRC a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BRC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 96 | 4% |
| Analysts Target Price | 96 | 4% |
| ValueRay Target Price | 109.9 | 19.1% |
BRC Fundamental Data Overview February 02, 2026
P/E Forward = 13.3511
P/S = 2.6458
P/B = 3.2426
P/EG = 2.5
Revenue TTM = 1.54b USD
EBIT TTM = 251.4m USD
EBITDA TTM = 292.9m USD
Long Term Debt = 115.9m USD (from longTermDebt, last quarter)
Short Term Debt = 16.6m USD (from shortTermDebt, last quarter)
Debt = 176.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.90m USD (from netDebt column, last quarter)
Enterprise Value = 4.07b USD (4.08b + Debt 176.8m - CCE 182.7m)
Interest Coverage Ratio = 54.66 (Ebit TTM 251.4m / Interest Expense TTM 4.60m)
EV/FCF = 25.48x (Enterprise Value 4.07b / FCF TTM 159.9m)
FCF Yield = 3.92% (FCF TTM 159.9m / Enterprise Value 4.07b)
FCF Margin = 10.37% (FCF TTM 159.9m / Revenue TTM 1.54b)
Net Margin = 12.74% (Net Income TTM 196.4m / Revenue TTM 1.54b)
Gross Margin = 50.59% ((Revenue TTM 1.54b - Cost of Revenue TTM 761.9m) / Revenue TTM)
Gross Margin QoQ = 51.53% (prev 50.40%)
Tobins Q-Ratio = 2.27 (Enterprise Value 4.07b / Total Assets 1.79b)
Interest Expense / Debt = 0.68% (Interest Expense 1.21m / Debt 176.8m)
Taxrate = 21.23% (14.5m / 68.5m)
NOPAT = 198.0m (EBIT 251.4m * (1 - 21.23%))
Current Ratio = 2.07 (Total Current Assets 662.4m / Total Current Liabilities 320.7m)
Debt / Equity = 0.14 (Debt 176.8m / totalStockholderEquity, last quarter 1.24b)
Debt / EBITDA = -0.02 (Net Debt -5.90m / EBITDA 292.9m)
Debt / FCF = -0.04 (Net Debt -5.90m / FCF TTM 159.9m)
Total Stockholder Equity = 1.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.48% (Net Income 196.4m / Total Assets 1.79b)
RoE = 16.63% (Net Income TTM 196.4m / Total Stockholder Equity 1.18b)
RoCE = 19.38% (EBIT 251.4m / Capital Employed (Equity 1.18b + L.T.Debt 115.9m))
RoIC = 15.43% (NOPAT 198.0m / Invested Capital 1.28b)
WACC = 7.97% (E(4.08b)/V(4.26b) * Re(8.29%) + D(176.8m)/V(4.26b) * Rd(0.68%) * (1-Tc(0.21)))
Discount Rate = 8.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.11%
[DCF Debug] Terminal Value 79.81% ; FCFF base≈152.0m ; Y1≈170.6m ; Y5≈227.4m
Fair Price DCF = 90.49 (EV 3.94b - Net Debt -5.90m = Equity 3.95b / Shares 43.6m; r=7.97% [WACC]; 5y FCF grow 14.16% → 2.90% )
EPS Correlation: -2.49 | EPS CAGR: -44.01% | SUE: -4.0 | # QB: 0
Revenue Correlation: 85.97 | Revenue CAGR: 6.68% | SUE: 1.04 | # QB: 2
EPS next Quarter (2026-04-30): EPS=1.35 | Chg30d=+0.010 | Revisions Net=+1 | Analysts=2
EPS current Year (2026-07-31): EPS=5.04 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+9.7% | Growth Revenue=+6.0%
EPS next Year (2027-07-31): EPS=5.50 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+8.9% | Growth Revenue=+3.8%